Second Sight Medical Products Inc (EYES) Releases Earnings Results, Misses Expectations By $-0.02 EPS

Second Sight Medical Products Inc (EYES) reported quarterly earnings results on Thursday, Jul-28-2016. The company reported $-0.17 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $-0.15. The company posted revenue of $1.00 million in the period, compared to analysts expectations of $1.40 million. The company’s revenue was down -63.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.12 EPS.

Second Sight Medical Products Inc closed down -0.01 points or -0.24% at $4.12 with 2,29,855 shares getting traded on Thursday. Post opening the session at $4.14, the shares hit an intraday low of $4.1 and an intraday high of $4.2 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

In a different news, on Jun 7, 2016, Edward David Randolph (VP of Manufacturing) sold 5,104 shares at $4.01 per share price. According to the SEC, on Jun 6, 2016, Robert J. Greenberg (Chairman of Board) sold 8,571 shares at $4.10 per share price. On Dec 7, 2015, Anne-marie Juliette Ripley (VP of Regulatory Affairs) sold 2,500 shares at $5.50 per share price, according to the Form-4 filing with the securities and exchange commission.

Second Sight Medical Products Inc. is a medical device company that develops manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product the Argus II System treats outer retinal degenerations such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision that normally sighted people have. The Argus II Retinal Prosthesis System consists of an implant a small portable computer and a pair of glasses with a miniature video camera. The Argus II system received Conformite Europeenne (CE) Mark approval for marketing and sales in the European Union (EU) and approval by the United States Food and Drug Administration (FDA) for marketing and sales in the United State. The Company also markets the Argus II system in Canada Turkey and at one medical center in Saudi Arabia.

Second Sight Medical Products Inc

Leave a Reply

Second Sight Medical Products Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Second Sight Medical Products Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.